FY2028 EPS Estimates for argenx Boosted by Leerink Partnrs

argenx SE (NASDAQ:ARGX) – Investment analysts at Leerink Partnrs upped their FY2028 EPS estimates for argenx in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn $34.69 per share for the year, up from their previous forecast of $34.23. The consensus estimate for argenx’s current full-year earnings is $2.78 per share. Leerink Partnrs also issued estimates for argenx’s FY2029 earnings at $41.83 EPS.

A number of other brokerages have also recently weighed in on ARGX. Deutsche Bank Aktiengesellschaft cut shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Wells Fargo & Company boosted their price objective on argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. JMP Securities upped their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $717.00 target price (up from $670.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Truist Financial reissued a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Stock Performance

Shares of ARGX opened at $671.74 on Thursday. The company’s 50 day simple moving average is $635.64 and its 200 day simple moving average is $574.35. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The company has a market capitalization of $40.81 billion, a price-to-earnings ratio of -763.34 and a beta of 0.58.

Institutional Trading of argenx

Large investors have recently bought and sold shares of the business. Creative Planning raised its holdings in shares of argenx by 15.5% during the second quarter. Creative Planning now owns 3,528 shares of the company’s stock valued at $1,517,000 after purchasing an additional 474 shares during the period. Sanctuary Advisors LLC bought a new position in argenx in the second quarter worth approximately $755,000. GAMMA Investing LLC raised its position in shares of argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares during the period. Perpetual Ltd bought a new position in shares of argenx in the 3rd quarter worth $76,314,000. Finally, Ritholtz Wealth Management bought a new position in shares of argenx in the 3rd quarter worth $262,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.